Revision history of "12012 — MIMEDI" (Q190706)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

16 May 2022

9 March 2022

13 January 2022

12 January 2022

6 December 2021

1 December 2021

  • curprev 06:2206:22, 1 December 2021DG Regio talk contribs 13,655 bytes +1,458 Created claim: summary (P836): Innovative (Medien-)Arzneimittel sind in jüngster Zeit entstanden, um neue Behandlungslösungen für Patienten in therapeutischen Sackgassen anzubieten. Diese Arzneimittel basieren auf der Verwendung von „Arzneimitteln“ Zellen. Die Herstellung dieser Arzneimittel erfordert jedoch die Anwendung komplexer und damit kostspieliger Technologien. MiMédi hat sich zum Ziel gesetzt, ihre Fertigung zu rationalisieren, indem sie neue technische Lösungen bere...

27 November 2021

  • curprev 11:0811:08, 27 November 2021DG Regio talk contribs 12,197 bytes −1,529 Removed claim: summary (P836): Les médicaments innovants (Médi) ont récemment émergé afin de suggestr de nouvelles solutions de traitement pour les patienten en impasse thérapeutique. CES Médi sont basés sur l’utilization de cellules „médicaments“. Oder, la fabrication de ces médicaments nécessite de mettre en oeuvre des technologies complexes et donc coûteuses. MiMédi a pour ambition de rationalizer leur fabrication en apportant de nouvelles solutions techniques et en opti...

26 November 2021

  • curprev 21:4021:40, 26 November 2021DG Regio talk contribs 13,726 bytes +1,529 Created claim: summary (P836): Les médicaments innovants (Médi) ont récemment émergé afin de suggestr de nouvelles solutions de traitement pour les patienten en impasse thérapeutique. CES Médi sont basés sur l’utilization de cellules „médicaments“. Oder, la fabrication de ces médicaments nécessite de mettre en oeuvre des technologies complexes et donc coûteuses. MiMédi a pour ambition de rationalizer leur fabrication en apportant de nouvelles solutions techniques et en optimi...
  • curprev 13:3013:30, 26 November 2021DG Regio talk contribs 12,197 bytes +75 Changed label, description and/or aliases in de: translated_label

29 October 2020

13 October 2020

  • curprev 09:2909:29, 13 October 2020DG Regio talk contribs 12,556 bytes +75 Changed label, description and/or aliases in 1 language: translated_label
  • curprev 09:2909:29, 13 October 2020DG Regio talk contribs 12,481 bytes −75 Changed label, description and/or aliases in 1 language: remove_english_label
  • curprev 09:2909:29, 13 October 2020DG Regio talk contribs 12,556 bytes +1,393 Created claim: summary (P836): Innovative medicines (medium) have recently emerged to propose new treatment solutions for patients with therapeutic deadlocks. These media are based on the use of “drug” cells. However, the manufacture of these drugs requires the implementation of complex and therefore costly technologies. MiMédi aims to streamline their manufacturing by providing new technical solutions and optimising all the steps necessary for their production. To do so, MiM...
  • curprev 09:2909:29, 13 October 2020DG Regio talk contribs 11,163 bytes −965 Removed claim: summary (P836): Innovative medicines (Médi) have recently emerged in order to propose new treatment solutions for patients in therapeutic impasse. These are based on the use of medicines cells. However, the manufacture of these medicines requires the implementation of complex and thus expensive technologies. Migri’s ambition is to streamline production by providing new technical solutions and optimising all the steps needed to produce them. In order to get in...

16 July 2020

16 June 2020

10 June 2020

29 May 2020

26 March 2020

26 February 2020

25 February 2020

  • curprev 09:2609:26, 25 February 2020DG Regio talk contribs 7,687 bytes +965 Created claim: summary (P836): Innovative medicines (Médi) have recently emerged in order to propose new treatment solutions for patients in therapeutic impasse. These are based on the use of medicines cells. However, the manufacture of these medicines requires the implementation of complex and thus expensive technologies. Migri’s ambition is to streamline production by providing new technical solutions and optimising all the steps needed to produce them. In order to get invo...

17 February 2020

31 January 2020

30 January 2020

15 January 2020